Determination of Regulatory Review Period for Purposes of Patent Extension; AGAMREE

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for AGAMREE, a human drug product, and is publishing this notice as required by law. The FDA made this determination due to patent extension applications submitted to the US Patent and Trademark Office (USPTO).